Dermatopharmacologic investigations of halobetasol propionate in comparison with clobetasol 17-propionate
- PMID:1757603
- DOI: 10.1016/0190-9622(91)70312-p
Dermatopharmacologic investigations of halobetasol propionate in comparison with clobetasol 17-propionate
Abstract
Both halobetasol propionate and clobetasol 17-propionate exerted very marked antiinflammatory, antiproliferative, and vasoconstrictive effects during evaluation in a range of dermatopharmacologic models. Halobetasol propionate was distinctly more potent than clobetasol 17-propionate in the ultraviolet-induced dermatitis inhibition assay in guinea pigs and in the rat model of oxazolone-induced late inflammatory reaction. Halobetasol propionate was slightly more potent than clobetasol 17-propionate in inhibiting croton oil-induced ear edema in rats and mice and in the mouse model of oxazolone-induced early inflammatory reaction. In the cotton-pellet granuloma assay in rats and the epidermal hyperplasia inhibition assay in guinea pigs, halobetasol propionate was distinctly superior to clobetasol 17-propionate. There was a trend in favor of halobetasol propionate in the cutaneous vasoconstriction assay performed in volunteers with ethanol solutions of halobetasol propionate and clobetasol 17-propionate. In a further vasoconstriction assay, performed with a 0.05% concentration of both halobetasol propionate and clobetasol 17-propionate in cream and ointment formulations, halobetasol propionate ointment yielded the highest blanching score. In a hypothalamic-pituitary-adrenal axis study in volunteers, effects of 0.05% halobetasol propionate ointment and 0.05% clobetasol 17-propionate ointment on serum cortisol levels were similar. The overall efficacy trends demonstrated in these dermatopharmacologic studies are in agreement with predictions made from corticosteroid structure and activity relationships and the results of two clinical trials comparing halobetasol propionate and clobetasol 17-propionate ointments in the treatment of plaque psoriasis.
Similar articles
- A double-blind, multicenter comparison of 0.05% halobetasol propionate ointment and 0.05% clobetasol propionate ointment in patients with chronic, localized plaque psoriasis.Goldberg B, Hartdegen R, Presbury D, Smith EH, Yawalkar S.Goldberg B, et al.J Am Acad Dermatol. 1991 Dec;25(6 Pt 2):1145-8. doi: 10.1016/0190-9622(91)70313-q.J Am Acad Dermatol. 1991.PMID:1757605Clinical Trial.
- Halobetasol propionate cream by day and halobetasol propionate ointment at night for the treatment of pediatric patients with chronic, localized plaque psoriasis and atopic dermatitis.Herz G, Blum G, Yawalkar S.Herz G, et al.J Am Acad Dermatol. 1991 Dec;25(6 Pt 2):1166-9. doi: 10.1016/0190-9622(91)70319-w.J Am Acad Dermatol. 1991.PMID:1757611Clinical Trial.
- A review of two controlled multicenter trials comparing 0.05% halobetasol propionate ointment to its vehicle in the treatment of chronic eczematous dermatoses.Guzzo CA, Weiss JS, Mogavero HS, Ellis CN, Zaias N, Lowe NJ, Kerdel FA, Milbauer JJ, Bernhard JD, Whitmore C, et al.Guzzo CA, et al.J Am Acad Dermatol. 1991 Dec;25(6 Pt 2):1179-83. doi: 10.1016/0190-9622(91)70322-s.J Am Acad Dermatol. 1991.PMID:1757614Clinical Trial.
- Vitamin D and topical therapy.Lebwohl M.Lebwohl M.Cutis. 2002 Nov;70(5 Suppl):5-8.Cutis. 2002.PMID:12467332Review.
- Topical halobetasol propionate in the treatment of plaque psoriasis: a review.Rivera AM, Hsu S.Rivera AM, et al.Am J Clin Dermatol. 2005;6(5):311-6. doi: 10.2165/00128071-200506050-00004.Am J Clin Dermatol. 2005.PMID:16252930Review.
Cited by
- Time-dependent cytokine production in the croton oil-induced mouse ear oedema and inhibition by prednisolone.Towbin H, Pignat W, Wiesenberg I.Towbin H, et al.Inflamm Res. 1995 Aug;44 Suppl 2:S160-1. doi: 10.1007/BF01778311.Inflamm Res. 1995.PMID:8548377No abstract available.
- Effect of Different Skin Penetration Promoters in Halobetasol Propionate Permeation and Retention in Human Skin.Carvajal-Vidal P, Mallandrich M, García ML, Calpena AC.Carvajal-Vidal P, et al.Int J Mol Sci. 2017 Nov 21;18(11):2475. doi: 10.3390/ijms18112475.Int J Mol Sci. 2017.PMID:29160818Free PMC article.
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical